leflunomide   Click here for help

GtoPdb Ligand ID: 6825

Synonyms: Arabloc® | Arava® | HWA 486 | HWA-486 | lefunamide | SU-101
Approved drug Immunopharmacology Ligand
leflunomide is an approved drug (FDA (1998), EMA (1999))
Compound class: Synthetic organic
Comment: Inhibits dihydroorotate dehydrogenase.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 55.13
Molecular weight 270.06
XLogP 2.79
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES O=C(c1cnoc1C)Nc1ccc(cc1)C(F)(F)F
Isomeric SMILES O=C(c1cnoc1C)Nc1ccc(cc1)C(F)(F)F
InChI InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)
No information available.
Summary of Clinical Use Click here for help
Used to treat active rheumatoid arthritis (improve physical function and slow progression), prevention of acute/chronic rejection following organ transplant (as an FDA designated orphan drug).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Leflunomide acts as a pyrimidine synthesis inhibitor. It is rapidly and almost completely metabolized following oral administration to its pharmacologically active metabolite, A77 1726. Its mechanism of action has not been fully resolved but appears to be associated with a reduction in the pyrimidine level, which in turn has an inhibitory effect on autoimmune T cells [1].
External links Click here for help